CEO Clips: John Docherty | Lexaria Biosciences | Improving the Delivery for Medical Cannabinoids
John Docherty, President of Lexaria Bioscience explains the company’s technology for improved delivery of medical cannabinoids. I’m a pharmacologist with a background in the bio-pharmaceutical sector, and a focus in the development of absorption technologies for drug delivery.
Lexaria is a biotech company with patented lipid-based delivery technology that enhances taste and absorption of beneficial molecules like CBD and THC found in cannabis edible products.
We can apply that same technology to other active substances like nicotine which has beneficial properties, to things like fat-soluble vitamins, and things like pain relievers such as ASA, ibuprofen and things of that nature.
As a company, we look to license our tech to third-party companies. We are doing so in the United States currently, and we look to do so here in our own backyard in Canada when the regulations allow. We look to leverage our tech for better tasting, faster acting and more potent edible products with those actives.
We have conducted human tissue in-vitro, and also human focus studies, through which we’ve demonstrated as much as a 5 to 10-fold increase in the absorption of molecules like CBD and THC, and also on onset of action and as little as 15 to 20 minutes. As well, test subjects rate our technology and products better in flavor profile.
Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery.
Subscribe to receive more investment opportunities videos: http://bit.ly/Subscribe2BTV